{"organizations": [], "uuid": "1a6b14044241c51663e393c2f55ef83ff8b7123a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-juno-therapeutics-says-if-deal-ter/brief-juno-therapeutics-says-if-deal-terminated-by-co-or-celgene-fee-of-300-mln-may-be-payable-by-co-to-celgene-idUSFWN1PH0OF", "country": "US", "domain_rank": 408, "title": "BRIEF-Juno Therapeutics Says If Deal Terminated By Co Or Celgene, Fee Of $300 Mln May Be Payable By Co To Celgene", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-22T15:44:00.000+02:00", "replies_count": 0, "uuid": "1a6b14044241c51663e393c2f55ef83ff8b7123a"}, "author": "", "url": "https://www.reuters.com/article/brief-juno-therapeutics-says-if-deal-ter/brief-juno-therapeutics-says-if-deal-terminated-by-co-or-celgene-fee-of-300-mln-may-be-payable-by-co-to-celgene-idUSFWN1PH0OF", "ord_in_thread": 0, "title": "BRIEF-Juno Therapeutics Says If Deal Terminated By Co Or Celgene, Fee Of $300 Mln May Be Payable By Co To Celgene", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-juno therapeutics says if deal terminated by co or celgene", "sentiment": "negative"}, {"name": "brief-juno therapeutics says if deal terminated by co", "sentiment": "negative"}, {"name": "sec", "sentiment": "none"}, {"name": "celgene reuters staff", "sentiment": "none"}, {"name": "celgene corp", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "celgene", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "#Market News  45 PM / in 10 minutes BRIEF-Juno Therapeutics Says If Deal Terminated By Co Or Celgene, Fee Of $300 Mln May Be Payable By Co To Celgene Reuters Staff 1 Min Read \nJan 22 (Reuters) - Celgene Corp: \n* JUNO THERAPEUTICS SAYS IF DEAL TERMINATED BY CO OR CELGENE UPON SPECIFIED CONDITIONS, FEE OF $300 MILLION MAY BE PAYABLE BY CO TO CELGENE - SEC FILING \n* JUNO THERAPEUTICS SAYS DEAL AGREEMENT PROVIDES CELGENE TO HAVE TO PAY CO REVERSE TERMINATION FEE OF $600 MILLION IF DEAL TERMINATED UNDER SOME CONDITIONS Source text: ( bit.ly/2n0Tiwe ) Further company coverage:", "external_links": [], "published": "2018-01-22T15:44:00.000+02:00", "crawled": "2018-01-22T16:02:08.008+02:00", "highlightTitle": ""}